Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection  by Quan, Fu-Shi et al.
Virology 430 (2012) 127–135Contents lists available at SciVerse ScienceDirectVirology0042-68
http://d
n Corr
E-m
1 Cu
of Medijournal homepage: www.elsevier.com/locate/yviroInﬂuenza M1 VLPs containing neuraminidase induce
heterosubtypic cross-protectionFu-Shi Quan a, Min-Chul Kimb, Byeong-Jae Lee b,1, Jae-Min Song c,
Richard W. Compans b, Sang-Moo Kang d,n
a Department of Medical Zoology, Kyung Hee University School of Medicine, Seoul 130-701, Korea
b Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA
c Department of Global Medical Science, Sungshin Women’s University, Seoul, Korea
d Center for Inﬂammation, Immunity and Infection, and Department of Biology, Georgia State University, Atlanta, Georgia 30303, USAa r t i c l e i n f o
Article history:
Received 17 January 2012
Returned to author for revisions
30 April 2012
Accepted 11 May 2012
Available online 2 June 2012
Keywords:
Inﬂuenza
Virus-like particles
Neuraminidase
Protection22/$ - see front matter & 2012 Elsevier Inc. A
x.doi.org/10.1016/j.virol.2012.05.006
esponding author.
ail address: skang24@gsu.edu (S.-M. Kang).
rrent address: Department of Microbiology, U
cine, 12800 E. 19th Ave. MS 8333, RC1North-9a b s t r a c t
Inﬂuenza virus like particles (VLPs) containing hemagglutinin were previously demonstrated to induce
protection against the homologous strains. However, little information is available on the protective
role of neuraminidase (NA), the second major glycoprotein. In this study, we developed VLPs (NA VLPs)
containing NA and M1 derived from A/PR/8/34 (H1N1) inﬂuenza virus, and investigated their ability to
induce protective immunity. Intranasal immunization with NA VLPs induced serum antibody responses
to H1N1 and H3N2 inﬂuenza A viruses as well as signiﬁcant neuraminidase inhibition activity.
Importantly, mice immunized with NA VLPs were 100% protected against lethal infection by the
homologous A/PR/8/34 (H1N1) as well as heterosubtypic A/Philippines/82 (H3N2) virus, although body
weight loss was observed after lethal challenge with heterosubtypic H3N2 virus. The present study
therefore provides evidence that inﬂuenza VLPs containing M1 and NA are capable of inducing
immunity to homologous as well as antigenically distinct inﬂuenza A virus strains.
& 2012 Elsevier Inc. All rights reserved.Introduction
The principal target of currently licensed inﬂuenza vaccines is
hemagglutinin (HA), the most abundant viral surface antigen.
Antibody to the hemagglutinin (HA) of inﬂuenza viruses has virus
neutralizing activity and shows a correlation with protective
immunity to inﬂuenza. The current trivalent inﬂuenza vaccines
are standardized on the basis of the content of the HA compo-
nents. Sixteen HA subtypes have been identiﬁed among inﬂuenza
A viruses (Fouchier et al., 2005). The protective efﬁcacy of the
vaccine is highly dependent on the degree of homology between
the HA of the vaccine strain and the predicted epidemic strain
(Couch, 2008). However, current vaccines based on immunity to
HA do not provide good protection against antigenically hetero-
logous viruses (Wilson and Cox, 1990). The degree of HA sequence
diversity between subtypes is large and the antigenic properties
of the HA molecules of the virus vary because of mutation to
escape from the pressure of preexisting immunity (Fouchier et al.,
2005; Wilson and Cox, 1990).ll rights reserved.
niversity of Colorado School
403D, Aurora, CO 80045, USA.Neuraminidase (NA), the second major surface protein and
determinant of 9 serotypes, is not standardized in current
vaccines (Fouchier et al., 2005). It was proposed that the NA
molecules are relatively slower in antigenic evolution as com-
pared with the HA (Kilbourne et al., 1990). Antibodies against NA
do not block infection, but they were shown to inhibit the
enzymatic activity of NA, to cause virus aggregation, and limit
the spread of virus (Chen et al., 2000; Compans et al., 1969;
Johansson et al., 1989; Johansson and Kilbourne, 1993). Also, NA
antibodies could provide immunity to inﬂuenza in humans
(Couch et al., 1974; Murphy et al., 1972). In addition, the NA
protein has become an important target for antiviral drugs
(oseltamivir, zanamivir). Thus, it would be desirable to ensure
that inﬂuenza vaccines induce anti-NA antibodies as well.
Previous studies used different approaches to study the role of
NA in vaccination against inﬂuenza, demonstrating reduction in
morbidity and mortality. These include puriﬁed NA proteins
(Brett and Johansson, 2005; Deroo et al., 1996; Johansson, 1999;
Johansson et al., 1998; Martinet et al., 1997), DNA plasmid (Chen
et al., 2005; Chen et al., 2000; Li et al., 2006; Qiu et al., 2006;
Sandbulte et al., 2007), and a variety of live virus-vectored
vaccines expressing NA (Gao et al., 2006; Pavlova et al., 2009;
Qiao et al., 2003; Sylte et al., 2007; Webster et al., 1988).
However, preparation of soluble recombinant protein vaccines is
laborious and may increase the vaccine cost, and DNA vaccines
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require multiple immunizations. Recombinant live vectored vac-
cines may have concerns about anti-vector immunity and safety
for use in humans.
Inﬂuenza virus-like particles (VLPs) have been suggested as a
promising vaccine candidate against inﬂuenza (reviewed in (Kang
et al., 2009a)). Vaccination with VLPs containing HA was demon-
strated to induce protection to the homologous and closely
related inﬂuenza viruses of seasonal and potential pandemic
strains (Quan et al., 2007; Quan et al., 2010c; Song et al., 2010).
Protective immunity of inﬂuenza VLPs containing both HA and NA
was also reported (; Bright et al., 2007, 2008; Pushko et al., 2007).
However, NA-mediated protective immune responses by vaccina-
tion with VLPs have not been well studied. In this study,
we generated inﬂuenza VLPs containing M1 and NA derived from
A/PR/8/34 virus (NA VLPs), and investigated their immunogeni-
city to homologous and heterosubtypic inﬂuenza viruses. Poten-
tial mechanisms of protection mediated by NA VLP vaccination
have been explored and are discussed.Results
Characterization of inﬂuenza VLPs containing neuraminidase
(NA VLPs)
To determine the immunogenicity and protective efﬁcacy of
neuraminidase (NA), we produced inﬂuenza NA VLPs in insect
cells by co-infecting with recombinant baculoviruses (rBVs)
expressing the M1 and NA proteins derived from PR8 (A/PR8/
1934) virus, and characterized the VLPs. The incorporation of NA
and M1 into VLPs was conﬁrmed by western blot (Fig. 1A). The
functional activity of NA incorporated into VLPs was found to be
dependent on concentration of VLPs as determined by a neur-
aminidase enzyme assay (Fig. 1B). Inﬂuenza HA VLPs without NA
did not show neuraminidase activity (Fig. 1B). The size and
morphology of NA VLPs resembled inﬂuenza virus particles
(Fig. 1C) although rod-like HA spikes were not detected. Taken
together, these results show that NA VLPs produced in insect cells
contain NA functional activity and are structurally similar to
inﬂuenza virions.
Vaccination with NA VLPs elicits antibody response speciﬁc to NA
To evaluate the immunogenicity of NA VLPs, mice (n¼12)
were immunized intranasally with 5 mg (total proteins) of NA
VLPs using a prime-boost regimen. At 2 weeks after priming, we
determined levels of total IgG serum antibodies binding to
inactivated A/PR8 virus or CV-1 cells infected with recombinant
vaccinia virus expressing NA (Fig. 2). Low levels of antibodies
binding to NA expressed on the surface of cells or inactivatedFig. 1. Characterization of N1 NA VLPs. (A) Inﬂuenza NA VLPs containing NA and M1 p
protein was detected by blotting with mouse serum prepared as described in methods
(relative luminence unit (RLU)). NA VLPs: M1 VLPs containing NA (derived from A/PR8
(derived from A/PR8 virus). (C) Electron microscopy of inﬂuenza NA VLPs.virus were observed after priming. After boost immunization,
signiﬁcantly higher levels of NA speciﬁc antibodies were induced
(Fig. 2A). Similarly high levels of antibodies binding to inactivated
A/PR8 virus were detected in boost immune sera (Fig. 2B). IgG
responses after boost were signiﬁcantly higher than those after
priming (Po0.01). When isotypes of antibodies to inactivated
A/PR8 virus were determined, IgG1 was detected at a signiﬁcantly
higher level than IgG2a (Fig. 2C). To determine the cross reactivity
of NA VLP immune sera, the heterosubtypic H3N2 (A/Philippines/
82) viral antigen was used as an ELISA coating antigen (Fig. 2D).
Substantial levels of total IgG and IgG1 isotype antibodies but not
IgG2a antibody speciﬁc to inactivated A/Philippines/82 virus were
observed (Fig. 2D). Overall, these results indicate that NA VLP
immunization induces antibodies reactive to the homologous as
well as heterosubtypic NA antigens.
Vaccination with NA VLPs induces complete protection against the
homologous virus without weight loss
Next, we determined whether immune sera from N1 VLP
vaccination would inhibit NA activity (Fig. 3A). Six-fold higher
levels of NA inhibition activity were found in immune sera
compared to naı¨ve sera (Po0.001). No signiﬁcant hemagglutinin
inhibition activity (HAI) or neutralizing activity was found in the
immune sera (data not shown). Therefore, immunization with NA
VLPs induces serum antibody responses that can inhibit neur-
aminidase activity.
To determine protective efﬁcacies, mice were challenged with
a high lethal dose of A/PR8/1934 virus (20 LD50) at 4 weeks after
boost immunization with NA VLPs. As shown in Fig. 3B and C, all
naı¨ve mice died after infection. In contrast, mice vaccinated with
NA VLPs were completely protected with 100% survival without
weight loss. These results show that VLPs containing NA can
confer completely protective immunity against lethal challenge in
a mouse model.
NA VLP vaccination provides effective control of challenge virus
replication
The efﬁciency of virus clearance in lungs provides a sensitive
indicator for assessing protective efﬁcacy. At day 4 post challenge,
mice were sacriﬁced and viral titers in lung extracts were deter-
mined. Compared to naı¨ve mouse control groups, mice immunized
with NA VLPs showed signiﬁcantly lower lung viral titers by 10,000
fold (Po0.001) (Fig. 4A). The production of the inﬂammatory
cytokine interferon gamma (IFN-g) was also determined in lungs
collected at day 4 after challenge infection. Naı¨ve mice infected with
A/PR8/34 virus showed high levels of IFN-g in lung extracts.
The vaccinated mice showed signiﬁcantly lower levels of IFN-g
similar to those in uninfected naı¨ve mice (Fig. 4B). Therefore, theseroteins on Western blot. NA VLPs (10, 5, 1 mg) were separated by SDS-PAGE. NA
. M1 protein was determined by anti-M1 IgG antibody. (B) Neuraminidase activity
virus), PR8 whole virus: inactivated whole virus, HA VLPs: M1 VLPs containing HA
Fig. 2. IgG, IgG1 and IgG2a antibody responses. Groups of mice were immunized with NA VLP intranasally with an interval of 4 weeks and blood samples were collected at
week 2 after prime (1st sera) and boost (2nd sera). Individual mouse serum was used and the average of antibody response from each group was determined. (A) IgG
antibody reactive to N1 NA derived from A/PR8 virus. CV-1 cells were infected with recombinant vaccinia virus expressing A/PR8 NA and used for cell surface ELISA
antigen. (B) IgG antibody reactive to the whole inactivated A/PR8 virus. (C) IgG1 and IgG2a isotype antibodies reactive to the whole inactivated A/PR8 (H1N1) virus. (D) IgG
and isotypes IgG1 and IgG2a antibodies reactive to the whole inactivated A/Phil (A/Philippines/82, H3N2 subtype) virus.
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immunity without disease symptoms and confers effective control
of viral replication, resulting in reduced proinﬂammatory cytokine
production.
NA VLP vaccination induces effective antibody secreting cell
responses
To determine antibody secreting cell responses (ASC), spleen or
bone marrow cells were harvested at day 4 post challenge infection
and cultured in vitro for 2 and 6 days. The number of B cells in a
memory state is relatively low with VLP vaccination and antigenic
challenge allows an easy detection of ASC responses indicating
anamnestic responses (Song et al., 2010). Signiﬁcantly higher levels
of antibodies speciﬁc to A/PR8/34 viral antigens were secreted into
supernatants after 6 days culture of splenocytes than those obtained
after 2 days culture (Po0.001, Fig. 5). Importantly, cells from bone
marrow produced substantial amounts of antibodies speciﬁc to
A/PR8 virus at day 2 post culture, which is signiﬁcantly higher than
those in spleen cell cultures at day 2 (Fig. 5). Levels of antibodies in
bone marrow cultures continued to increase during the 6 day of
culture (Po0.05, Fig. 5). These results indicate that vaccination with
NA VLPs can induce the generation of antibody secreting plasma cells
in bone marrow. In addition, NA VLPs vaccination can induce
memory B cells in spleens, which can rapidly differentiate into
antibody secreting plasma cells upon exposure to inﬂuenza viral
infection.
NA VLP vaccination induces heterosubtypic cross protection
To determine whether vaccination of mice with VLPs contain-
ing N1 NA (A/PR8, H1N1) can induce heterosubtypic cross
protection, immunized mice were challenged with a lethal dose
of A/Phil (H3N2) virus. At day 4 post challenge with A/Phil virus,lung virus titers were observed at approximately 20-fold lower
in NA VLP immunized mice compared to naı¨ve mice (Fig. 6A).
All naı¨ve mice infected with A/Phil virus died by day 7. Mice
vaccinated with N1 NA VLPs were 100% protected against lethal
challenge with A/Phil virus although substantial body weight loss
was observed (Fig. 6B and C). Immunized mice showed a recovery
in the body weight from day 9. In terms of virus clearance and
body weight changes, the protective efﬁcacy after heterosubtypic
virus challenge was lower compared to the protection against the
homologous virus. Nonetheless, the results provide evidence that
vaccination with VLPs containing NA may be able to confer cross-
protection.
Protective role of NA VLP immune sera
The capability of NA VLP immune sera to provide protection
was tested in naı¨ve mice. Although NA speciﬁc antibodies do not
have direct virus neutralizing activity, we wanted to determine
other possible immune mechanisms in providing protection.
Mixtures of a lethal dose of A/PR8 and NA VLP immune or naı¨ve
sera were used to intranasally infect naı¨ve mice. This method was
previously well used to assess the protective role of polyclonal
immune sera (Quan et al., 2010c; Song et al., 2011b). Naı¨ve mice
that were infected with a mixture of virus and naive sera showed
severe body weight loss reaching to 75% of original weight and
showed a 20% survival rate (Fig. 7A and B). In contrast, NA VLP
immune sera conferred complete protection to naı¨ve mice that
were infected with a lethal dose of A/PR8 virus. Therefore, these
results suggest that anti-NA immune sera play an important role
in providing protection.
Since NA antibodies do not have virus neutralizing activity, we
studied the potential roles of lung airway macrophage cells in
conferring anti-NA antibody-mediated protection (Fig. 7C and D).
Previous studies demonstrated the selective depletion of lung
Fig. 3. Protective immunity to the homologous A/PR8 virus. (A) Serum NA inhibition
activity against A/PR8 virus. NA inhibition activity was determined by using the
NA-Star inﬂuenza neuraminidase inhibitor resistance detection kit. Immune sera
were from N1 VLP-immunized mice and naı¨ve sera from naı¨ve mice. (B) Body
weight changes. (C) Survival rates. (B–C) At week 4 after boost, mice were
challenged with a lethal dose (20 LD50) of A/PR8 virus and were monitored
daily to record body weight changes and survival rates. Six mice were used in
each group.
Fig. 4. Virus titers and cytokine IFN-g in lungs. Lungs from individual mice in each group (
(A) and lung IFN-g concentrations (B) were determined. NA VLPþPR8: NA VLP vaccin
challenge.
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clodronate-liposomes (Bosio and Dow, 2005; McGill et al., 2008).
Similarly, we showed selective depletion of lung dendritic and
macrophage cells by intranasal administration of clodronate-
liposomes (Song et al., 2011a, 2011b). When naı¨ve mice were
pretreated with clodronate-liposome, these mice showed severe
body weight loss and 50% survival rate after infection with a
lethal dose of A/PR8 virus mixed with N1 VLP immune sera
(Fig. 7C and D). Whereas, sera from mice that had recovered from
sub-lethal infection with A/PR8 virus provided good protection
even in the group pretreated with clodronate-liposomes (Fig. 7C
and D), indicating that protective antibody responses to HA might
be different from those to NA in the mechanism of protection.
These results indicate that dendritic and macrophage cells might
be important for conferring NA immune serum-mediated
protection.Discussion
VLPs provide a promising platform of vaccine candidates
presenting an antigen in an immunogenic form. Although both
HA and NA are glycoproteins expressed on the surfaces of
inﬂuenza virions, the role of NA immune responses in conferring
vaccine- induced protective immunity has not been as well
investigated compared to that of HA. Among the factors in
limiting the study of NA-speciﬁc antibodies in protection is the6 mice) were collected at day 4 after A/PR8/34 virus challenge, and lung virus titers
ated mice with A/PR8 virus challenge. Naı¨veþPR8: Naı¨ve mice with A/PR8 virus
Fig. 5. Antibody-secreting cell (ASC) responses. Spleen and bone marrow samples
were collected from individual mice immunized with NA VLPs in each group
(6 mice) at day 4 post challenge. Antibody levels produced during in vitro cultures
for 2 days (D2) and 6 day (D6) as an indicator of ASC responses speciﬁc to the
A/PR8 virus were expressed in ng/ml as determined by ELISA.
Fig. 6. Protective immunity to the heterosubtypic A/Phil (H3N2) virus. Protection against the heterosubtypic A/Phil (H3N2) virus was assessed by determination of lung virus
titers, body weight changes and survival rates after A/Phil virus challenge (5 LD50). (A) Lung viral titers at day 4 post challenge. (B) Body weight changes after A/Phil
challenge. (C) Survival rates after A/Phil challenge. Six mice were used in each group.
Fig. 7. Protective efﬁcacy of NA VLP immune sera and effects of clodronate-liposomes. Immune sera collected from NA VLP vaccinated mice at 2 weeks after boost vaccination
were incubated with a lethal dose of A/PR8 virus at room temperature for 30 min. Groups of mice (n¼4) were intranasally infected with a lethal dose mixed with NA VLP
immune sera or naı¨ve sera. (A) Body weight changes. (B) Survival rates. (C–D) To deplete dendritic cells and alveolar macrophages in lungs, groups of naı¨ve mice (n¼4)
were intranasally instilled with clodronate-liposomes 4 h prior to lethal infection. A lethal dose of A/PR8 (H1N1) virus was incubated with sera collected from NA VLP
vaccinated mice, infected mice (Infection), or naı¨ve mice (Naı¨ve). Each mixture of virus and sera was used to infect naı¨ve mice with clodronate-liposome pretreatment.
(C) Body weight changes against A/PR8 virus. (D) Survival rates against A/PR8 virus.
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immunodominant effects of HA as an antigen were found to occur
when HA and NA are present in the same viral particle (Johansson
and Kilbourne, 1993; Johansson et al., 1987). Inﬂuenza VLPs
provide an excellent vehicle to present NA as the major vaccine
component in a membrane-anchored conformation. In this study,
we investigated the generation of VLPs containing N1 NA, their
immunogenicity, and protective immunity against homologous
and heterosubtypic inﬂuenza A viruses. Inﬂuenza M1 VLPs con-
taining NA were highly immunogenic inducing NA-speciﬁc func-
tional antibodies, and conferred protection against the
homologous H1N1 A/PR8 virus and the heterosubtypic H3N2 A/
Philippines/82 virus. The contribution of inﬂuenza M1 to protec-
tion is known to be minimal or not signiﬁcant (Chen et al., 1999;
Chen et al., 1998; Wiesener et al., 2011) despite the induction of
M1 speciﬁc antibodies (Chen et al., 1998). In a previous study,
mice immunized with 20 mg of total VLPs containing inﬂuenza M1
as a core protein did not induce detectable levels of antibodies
speciﬁc to M1 (Song et al., 2011b). Thus, immune responses to NA
in 5 mg NA VLPs are likely to be the major contributor to
protection observed in this study.Immunization with NA VLPs induced NA-speciﬁc antibody
responses that can inhibit neuraminidase activity. The pattern
of antibody isotypes provides insight into the potential immune
cells that are involved in inducing antibody responses to an
antigen (Mongini et al., 1982; Pulendran, 2004). Analysis of
antibody isotypes in immune sera showed that IgG1 antibody
was predominantly induced by immunization of mice (BALB/c)
with NA VLPs. Soluble recombinant HA protein antigens are also
known to induce IgG1 dominant antibody responses compared to
whole inactivated virus or HA VLP antigens, which are capable of
inducing IgG2a antibodies as a dominant isotype (Bright et al.,
2007, 2008; Song et al.). Therefore, it is speculated that vaccine
immunogens that are able to activate co-stimulatory and/or
innate immune sensing molecules on antigen presenting cells
may be effective in inducing IgG2a dominant isotype antibody
responses. In support of this hypothesis, we found in a prelimin-
ary study that mice with deﬁciency in MyD88, a key signaling
molecule for innate to adaptive immunity, displayed a signiﬁcant
defect in inducing IgG2a (or IgG2c) antibody responses after
inﬂuenza HA VLP immunization (data not shown). In addition,
our recent studies demonstrated that whole inactivated virus or
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dominant isotype antibody responses (Kim et al., 2010; Quan
et al., 2010b; Quan et al., 2009a). Probably, NA VLPs without HA,
which also lack hemagglutination activity, might be less effective
in inducing IgG2a dominant immune responses compared to HA
VLPs with hemagglutination activity.
The immune mechanisms by which NA-speciﬁc antibodies
confer protection appear to be different from those by HA speciﬁc
antibodies induced by conventional vaccination. Antibodies spe-
ciﬁc to HA are able to neutralize and block the infection of
inﬂuenza virus, possibly inducing sterilizing immunity. In con-
trast, NA antibodies block the release of infectious virus from the
surface of infected cells, causing virus aggregation, limiting viral
spread, and thus allowing the host to develop adaptive immunity
(Compans et al., 1969; Schulman et al., 1968). Anti-NA sera failed
to prevent infection of cells in vitro, but passive immunization
reduced morbidity and mortality in mice after infection (Kasel
et al., 1973; Schulman et al., 1968; Webster et al., 1968). We
found that immune responses to NA VLP vaccination effectively
controlled lung viral replication resulting in several thousand-fold
lower titers and complete protection without morbidity, despite
not being able to prevent the infection. This study also suggests
that protection by NA VLP immune sera seems to be dependent
on the intactness of lung dendritic and macrophage cells. This is
suggested by the ﬁnding of reduced protection when mice were
treated with clodronate; one interpretation is that NA-speciﬁc
antibodies limit infection in a macrophage-dependent manner.
Another interpretation is that multiple immune mediators con-
tribute toward protection; macrophages provide some control of
infection; when this cell population is absent, overall protection is
signiﬁcantly less, since residual protection reﬂects the contribu-
tion of NA-speciﬁc antibodies alone and no longer the sum of
innate and NA-speciﬁc responses. In contrast, immune sera from
infected mice were protective independent of lung dendritic and
macrophage cells, indicating the role of virus-neutralizing activity
in mediating protection.
Our previous studies demonstrated that immunization with
HA VLP vaccines (HAþM1) induced strong protective immunity
and high virus neutralizing titers (Quan et al., 2010a; Quan et al.,
2008b; Quan et al., 2009b). Low doses in a range of 0.2 mg to
0.5 mg of total proteins of HA VLPs were capable of providing 100%
protection against homologous virus challenge without body
weight loss (Quan et al., 2009b). In this study, we used 5 mg of
total proteins of NA VLPs. This indicates that HA is likely to be a
more effective immunogen than NA in providing protection
against homologous virus.
Regarding heterosubtypic protection, we reported that inﬂu-
enza VLPs containing HA which originated from either A/PR8
(H1N1) or A/Aichi/68 (H3N2) virus did not confer protection
against an antigenically different strain (A/Philippines/82) (Quan
et al., 2008b). NA DNA vaccines were poor in inducing hetero-
subtypic immunity, not providing protection against heterosub-
typic H1N1 or H7N7 viruses although they provided survival
protection against homologous or heterologous virus within the
same subtype (Chen et al., 2000; Webster et al., 1988). The cross
protection by NA vaccines was also weak or partial if the strains
were distantly related, even within the same subtype (Sandbulte
et al., 2007; Sylte et al., 2007). In the present study, vaccination
with N1 NA VLPs provided 100% survival protection after lethal
challenge with the H3N2 virus. Since NA VLP vaccine was
administered intranasally, mucosal responses such as the induc-
tion of IgA antibody might have contributed to heterosubtypic
protection, which remains to be determined. NA VLPs would also
be a promising supplementary vaccine which is capable of
enhancing cross protection. However, the heterosubtypic cross
protection against the H3N2 virus (A/Philippines/82) was lowsince there was visible body weight loss and relatively high lung
viral titers compared to the homologous protection. The NA VLP
immune sera showed higher binding to the homologous virus
compared to the heterologous virus, correlating with the degree
of protection. Previous studies with HA-containing VLPs used very
high challenge doses, making it difﬁcult to compare the efﬁcacy of
HA and NA VLPs. Considering natural infections are sublethal in
most humans, the relatively low challenge doses used for these
NA VLP studies are relevant. The extent to which NA and HA VLP
vaccines protect against heterologous infection will be compared
in future studies.
Overall, the immunity to NA after vaccination is likely to induce
protection against homologous or antigenically closely related strains
but its protective efﬁcacy against antigenically distinct strains may
be low. The levels of NA antibody would be an important factor in
protection. However, there is a concern that human inﬂuenza
vaccines do not contain enough NA protein to induce a strong
protective antibody response to NA. A low level of antibodies against
NA is induced by immunization with either live-attenuated inﬂuenza
vaccine or conventional inactivated monovalent vaccine, and the
humoral immune response is skewed toward HA (Brett and
Johansson, 2005; Johansson et al., 1989). To address this concern,
previous studies demonstrated enhanced efﬁcacy of protection
against homologous and heterologous viruses by co-immunizing
with HA and NA vaccines, using recombinant vaccines co-expressing
HA and NA, or use of a high dosage of inﬂuenza vaccine (Brett and
Johansson, 2005; Cate et al., 2010; Chen et al., 1999; Johansson and
Brett, 2007; Johansson et al., 1998; Pavlova et al., 2009; Qiao et al.,
2003). In this regard, NA VLPs might be a promising candidate
vaccine for use in combination with current vaccination to extend
the level of cross protection.Materials and methods
Virus and cells
Inﬂuenza A viruses, A/PR/8/1934 (H1N1, abbreviated as A/PR8)
and A/Philippines/2/82 (A/Phil) were grown in 10-day old
embryonated hen’s eggs and puriﬁed from allantoic ﬂuid by using
a discontinuous sucrose gradient (15%, 30% and 60%) layers.
The puriﬁed virus was inactivated by mixing the virus with
formalin at a ﬁnal concentration of 1:4000 (v/v) as described
(Novak et al., 1993; Quan et al., 2008a; Sha and Compans, 2000).
Inactivation of the virus was conﬁrmed by a plaque assay on
conﬂuent monolayer Madin-Darby canine kidney (MDCK) cells
and inoculation of the virus into 10-day old embryonated hen’s
eggs. For use in challenge experiments, mouse adapted A/PR8 and
A/Phil viruses were prepared as lung homogenates of infected
mice. Spodoptera frugiperda Sf9 cells were maintained in suspen-
sion in serum free SF900II medium (GIBCO-BRL) at 27 1C in
spinner ﬂasks. MDCK and CV-1 cells were grown and maintained
in Dulbecco’s modiﬁed Eagle’s medium (DMEM).Preparation of inﬂuenza NA VLPs and HA VLPs
To clone a NA gene, inﬂuenza A/PR8 virus was used to infect
MDCK cells and total viral RNA was extracted using RNeasy Mini kit
(Qiagen). Reverse transcription (RT) and PCR were performed on
extracted viral RNA using One-Step RT-PCR system (Invitrogen) with
NA gene speciﬁc oligonucleotide primers. The following primer pairs
were used for the synthesis of NA: 5’-AAAGAATTCAAAATGAATCCA
AATCA GAAAATAATA-3’ and 5’-TTACTCGAGCTACTTGTCAATGCT-
GAATG GCAACT-3’. Following RT-PCR, a PCR DNA fragment obtained
by the NA gene speciﬁc primer pair was cloned into the pBlueScriptII
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sequences of the NA gene was conﬁrmed by DNA sequencing.
The construct of a baculovirus (BV) expressing inﬂuenza A M1
was prepared as previously described (Quan et al., 2007). To
generate a recombinant baculovirus (rBV) expressing NA, the
transfer vector, pFastBac plasmid and recombinant Bacmid bacu-
lovirus DNAs (rAcNPV) containing PR8 NA isolated from trans-
formed DH10Bac cells were used to transfect Sf9 insect cells as
described (Kang et al., 2009b). To produce VLPs, Sf9 cells were co-
infected with rBVs expressing NA and M1 at a multiplication of
infection 2 and 1 respectively, and culture supernatants contain-
ing released VLPs were harvested after 2–3 day of culture post
infection. After removing cell debris by low-speed centrifugation
(2000 g for 20 min at 4 1C), inﬂuenza M1-derived NA VLPs (NA
VLPs) in cleared culture supernatants were puriﬁed by 20%, 30%
and 60% sucrose gradient ultracentrifugation. The NA VLPs were
found to be located in the fraction between 30% and 60% sucrose.
Characterization of inﬂuenza VLPs containing A/PR8 NA was
performed by western blot using mouse polyclonal antibodies
(described below) against recombinant vaccinia virus encoding A/
PR8 NA. Anti-M1 antibody (Genesis Biotech Inc) was used to
determine M1 in the NA VLPs. Neuraminidase activity of puriﬁed
inﬂuenza NA VLPs were estimated by NA-Star inﬂuenza neur-
aminidase inhibitor resistance detection kit (Applied Biosystems).
Inﬂuenza M1 VLPs containing HA derived from A/PR8 (HA VLPs)
were prepared as described (Quan et al., 2007).
Electron microscopy
To examine budding of VLPs, Sf9 cells infected with rBVs
expressing M1 and NA were ﬁxed with 0.25% glutaraldehyde
and 1% osmium tetraoxide, dehydrated with ethanol, and then
embedded in Epon resin. Thin sections were stained with lead
citrate and uranyl acetate and observed by electron microscopy.
For negative staining of VLPs, sucrose gradient-puriﬁed VLPs (1 to
5 mg) were applied to a carbon-coated Formvar grid for 30 s.
Excess VLP suspension was removed by blotting with ﬁlter paper,
and the grid was immediately stained with 1% sodium phospho-
tungstate for 30 s. Excess stain was removed by ﬁlter paper, and
the samples were examined using a transmission electron
microscope.
Production of recombinant vaccinia virus encoding A/PR8
neuraminidase
The A/PR8 neuraminidase gene fragment from pFastBAc vector
described above was cloned in to pRB21 plasmid by the insertion
of neuraminidase between the EcoR I and Hind III enzyme sites.
Following infection and transfection of CV-1 cells with vaccinia
virus and pRB21 plasmid vector respectively, recombinant vacci-
nia virus was identiﬁed and isolated as described (Kang et al.,
2005). For analysis of the NA gene incorporation, the cell lysate
was ampliﬁed by PCR with NA speciﬁc primers. The recombinant
vaccinia viruses expressing NA were ampliﬁed, puriﬁed and
titrated. Recombinant vaccinia viruses (105 pfu) expressing NA
were injected into mice twice with a 4-week interval, and sera
were used for detection of neuraminidase in VLPs by western blot.
Neuraminidase activity
Neuraminidase activity assay was tested by incubation of NA
VLPs with a chemiluminescent derivative of neuraminic acid (NA-
Star Substrate) and following luminometric detection of the
reaction product using the NA-Star Inﬂuenza Neuraminidase
Inhibitor Resistance Detection Kit (Applied Biosystems). The
samples containing NA VLPs were diluted in NA-Star Assay Buffer[26 mM MES (pH 6.0) with 4 mM CaCl2]. Inactivated whole
inﬂuenza virus and HA VLPs were used as controls. Standard
neuraminidase was puriﬁed from bacteria Vibrio Cholerae (Roche,
1 U/ml). The luminometric detection was performed on a Mod-
ulus Microplate Multimode Reader (Turner Biosystems) and
chemiluminescent signal [Relative luminence unit (RLU)] was
presented.
Immunization and challenge
Female inbred BALB/c mice (Charles River) aged 6 to 8 weeks
were used. Groups of mice (12 mice per group) were intranasally
immunized twice with 5 mg (total proteins) of NA VLPs (0.006
units of enzyme activity) at a 4-week interval. For virus challenge,
isoﬂurane-anesthetized mice were intranasally infected with A/
PR8 virus (20 LD50), or A/Phil (5 LD50) in 50 ml of phosphate-
buffered saline (PBS) per mouse at week 4 after boost. For
measurement of immune response parameters, six mice from
each group were sacriﬁced prior to challenge or at day 4 post-
challenge. Mice were observed daily to monitor changes in body
weight and to record the mortality endpoint (25% loss in body
weight). We followed an approved Emory IACUC protocol for
this study.
Neuraminidase inhibition assay
Neuraminidase activity and inhibition assay was performed
following the manufacturer’s procedure of the NA-Star inﬂuenza
neuraminidase inhibitor resistance detection kit. Sera samples
from NA VLPs immunized sera and naı¨ve mouse were diluted in
NA-Star Assay Buffer and incubated with 105 pfu (plaque forming
unit) of A/PR8 live virus for 30 min at 37 1C. After incubation with
substrate, the chemiluminescent signal [Relative luminescence
unit (RLU)] was measured by injecting NA-Star accelerator.
Antibody responses
Blood samples were collected by retro-orbital plexus puncture
before immunization and at week 2 after the ﬁrst and second
immunization. Inﬂuenza virus speciﬁc antibodies IgG were deter-
mined in sera by enzyme-linked immunosorbent assay (ELISA) as
described previously (Quan et al., 2007). As coating antigens to
measure virus speciﬁc antibodies, we used two different coating
antigens. One is to determine the reactivity of sera to NA
expressed on CV-1 cells. To determine the cell surface-expressed
neuraminidase, CV-1 cells were infected with a recombinant
vaccinia virus encoding neuraminidase at MOI 0.5 and incubated
for 18 h. Cells were then washed and ﬁxed with 0.25% glutar-
aldehyde for 10 min and used for cell surface ELISA. Another is to
determine the reactivity to egg-grown inactivated inﬂuenza A/
PR8 (H1N1) or A/Phillipines/82 (A/Phil, H3N2) virus. Viral anti-
gens were coated onto the ELISA plates in coating buffer (0.1 M
sodium carbonate, pH 9.5, and 4 mg inactivated A/PR8 or A/Phil
viruses per ml) at 4 1C overnight. Serum IgG1 or IgG2a antibody
responses were determined using inactivated A/PR8 or A/Phil
virus as ELISA plate coating antigens (Quan et al., 2007, 2008b).
Hemagglutinin inhibition (HAI) assay and neutralizing activity
For determination of hemagglutination-inhibition (HAI) titers,
serum samples were ﬁrst treated with receptor destroying
enzyme by incubation overnight at 37 1C, and then incubated
30 min at 56 1C. Sera were serially diluted, mixed with 4 HA
units (HAU) of inﬂuenza A/PR8 virus, and incubated for 30 min
at room temperature prior to adding 0.5% chicken red blood
cells. The reciprocal of the highest serum dilution preventing
F.-S. Quan et al. / Virology 430 (2012) 127–135134hemagglutination was scored as the HAI titer as described (Quan
et al., 2010c). Virus neutralization was performed using by a
plaque assay on MDCK cells following a previously described
procedure (Quan et al., 2007).Lung viral titers and cytokine assays
Whole lung extracts prepared as homogenates using frosted
glass slides were centrifuged at 1000 RPM for 10 min to collect
supernatants. Lung tissues were placed on the glass slide, minced
and rinsed in the DMEM media repeatedly. The lung extract
containing viruses was then collected. Determination of viral
titers in lung extracts was performed using MDCK cells as
previously described (Quan et al., 2007). The detection limit of
the virus plaque assay is 50 pfu/ml. Cytokine ELISA was per-
formed as described (Quan et al., 2007). Ready-Set-Go IFN-g kits
(eBioscience, San Diego, CA) were used for detecting cytokine
levels in lung extracts following the manufacturer’s procedure.Virus-speciﬁc antibody secreting cell (ASC) responses from spleen and
bone marrow
Virus-speciﬁc antibody secreting cell responses were deter-
mined from bone marrow and spleen at day 4 post-challenge.
Since there is a correlation between the number of antibody
secreting cell spots and antibody levels secreted into culture
supernatants, ELISA was used to determine ASC response as
described (Kang et al., 2011; Song et al., 2010). Culture plates
(96-well) were coated with inactivated A/PR8 viral antigen over-
night. To measure antibody-producing cells in vitro, bone marrow
and spleen cells were prepared and placed in coated culture
plates. Cells from spleen or bone marrow were added to culture
plates after washing. Six mice were used in each group. After
2 and 6 days, cells were removed from plates and secondary
antibody IgG-HRP and substrate OPD was added and read at
450 nm (Song et al., 2010).Protective efﬁcacy test of immune sera and effects of clodronate-
liposomes
To measure protective efﬁcacy of immune sera in vivo, serum
samples (4 diluted) from immunized mice, infected mice after
recovery, or naı¨ve mice were pre-incubated with a lethal dose of
inﬂuenza virus at room temperature for 30 min as described
(Quan et al., 2008a; Song et al., 2011b). A mixture of a lethal
infectious dose of A/PR8 (H1N1) inﬂuenza virus (3 LD50) and sera
was administered to naive mice (n¼4 BALB/c), and body weight
changes and survival rates were monitored daily. Liposome-
encapsulated clodronate were prepared as previously described
(Van Rooijen and Sanders, 1994). Four hrs prior to infection with
virus- serum mixture, some groups of naı¨ve mice (n¼4 BALB/c)
were intranasally treated with clodronate-liposomes to deplete
dendritic and macrophage cells as described (Bosio and Dow,
2005; McGill et al., 2008; Thepen et al., 1991). Clodronate was a
kind gift of Roche Diagnostics GmbH, Mannheim, Germany.Statistics
All parameters were recorded for individuals within all groups.
Statistical comparisons of data were carried out using using the
t-test of the SigmaPlot program (Systat Software, Inc.). A P value
less than 0.05 was considered to be signiﬁcant.Acknowledgments
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